ArticleJournal of affective disorders2010
BDNF val66met polymorphism, white matter abnormalities and remission of geriatric depression.
Article in Journal of affective disorders, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- Microstructural brain abnormalities in medication-free patients with major depressive disorder: a systematic review and meta-analysis of diffusion tensor imaging.Journal of psychiatry & neuroscience : JPN · 2017Pooled it
- Resilience predicts remission in antidepressant treatment of geriatric depression.International journal of geriatric psychiatry · 2018Trial
- Genomic predictors of remission to antidepressant treatment in geriatric depression using genome-wide expression analyses: a pilot study.International journal of geriatric psychiatry · 2016Trial
- Neuroplasticity-based computerized cognitive remediation for treatment-resistant geriatric depression.Nature communications · 2014Trial
- Moderators of treatment response in late-life depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Review
- BDNF Gene Polymorphism and Antidepressant Response in Han Chinese Patients with First-Episode Late-Life Depression.Alpha psychiatry · 2025Article
- BDNF/BDNF-AS Gene Polymorphisms Modulate Treatment Response and Remission in Bipolar Disorder: A Randomized Clinical Trial.Journal of personalized medicine · 2025Article
- Serotonin transporter 5-HTTLPR polymorphism and escitalopram treatment response in patients with major depressive disorder.BMC psychiatry · 2024Article
- White matter microstructure changes in adults with major depressive disorder: evidence from diffusion magnetic resonance imaging.BJPsych open · 2023Article
- The Impact ofInternational journal of molecular sciences · 2023Article
- Mediation Analyses of the Role of Apathy on Motoric Cognitive Outcomes.International journal of environmental research and public health · 2022Article
- Effects of BDNF Val66Met Polymorphism on White Matter Microalterations of the Corpus Callosum in Patients with Panic Disorder in Korean Populations.Psychiatry investigation · 2020Article
- White matter disturbances in major depressive disorder: a coordinated analysis across 20 international cohorts in the ENIGMA MDD working group.Molecular psychiatry · 2020Article
- Neuroimaging Biomarkers for Predicting Treatment Response and Recurrence of Major Depressive Disorder.International journal of molecular sciences · 2020Review
- Article
- Regional White Matter Integrity Predicts Treatment Response to Escitalopram and Memantine in Geriatric Depression: A Pilot Study.Frontiers in psychiatry · 2020Article
- Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.CNS drugs · 2016Review
- White Matter Hyperintensity Accumulation During Treatment of Late-Life Depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015Article
- The BDNF gene Val66Met polymorphism as a modifier of psychiatric disorder susceptibility: progress and controversy.Molecular psychiatry · 2015Review
- Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications.Current psychiatry reports · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
objectiveThe polymorphism BDNF val66met of the brain derived neurotrophic factor (BDNF) is common, may increase the risk for depression, and affects BDNF secretion, critical for neuronal survival, plasticity, neurogenesis, and synaptic connectivity. Our objectives were: 1) to test the hypothesis that BDNF(val/met) status influences the remission rate of geriatric depression; 2) to explore whether the relationship between BDNF allelic status to remission is influenced by the presence of microstructural white matter abnormalities.
methodNon-demented older subjects with major depression had a 2-week placebo period, after which those with a Hamilton Depression Rating Scale (HDRS) of 18 or greater received escitalopram 10 mg daily for 12 weeks. Fractional anisotropy was determined in specific regions using the Reproducible Object Quantification Scheme (ROQS) software that operates on non-normalized data.
resultsBDNF(met) carriers were more likely to achieve remission than BDNF(val/val) homozygotes after 12 weeks of treatment with escitalopram 10 mg daily. Microstructural abnormalities in the corpus callosum, left superior corona radiata, and right inferior longitudinal fasciculum were also associated with lower remission rate. However, there were no significant interactions between BDNF(val66met) status and microstructural abnormalities in predicting remission. LIMITATIONS: Small number of subjects, focus on a single BDNF polymorphism, fixed antidepressant dose.
conclusionsDepressed older BDNF(met) carriers had a higher remission rate than BDNF(val/val) homozygotes. This effect was not related to microstructural white matter abnormalities, which predicted remission independently. We speculate that the relationship between BDNF(val66met) and remission is due to different effects of BDNF in brain structures related to mood regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.